Outstanding Junior African Scientist

This prize is awarded to a junior scientist (under 30 years old) based on a number of criteria, including innovation/ Intellectual Property, impact of research, publications and advocacy for health. It aims at fostering the research activities of the winners, with the aim of strengthening clinical research capacity in sub-Saharan Africa.

The Outstanding Senior African Scientist award consists of a recognition trophy and a cash prize of €10,000.

Recipients of the Outstanding Junior African Scientist Award



Mr Hannock Tweya

Mr. Hannock Tweya (Lighthouse Trust, Malawi) serves as the epidemiologist, monitoring and evaluations officer, and operations research supervisor for the Lighthouse. Mr. Tweya’s long publication list for one so young, reflects his integral involvement in the research operations. Data from the Lighthouse influences both Malawian and sub-Saharan ART programs. Mr. Tweya is often the creative force for the development of the protocols.







Dr Dominique J Pepper

Dr Dominique J Pepper is a physician-in-training at the University of Cape Town and has already completed the Part 1 Fellow of College of Physicians (South Africa) Examinations. He is affiliated with the Wilkinson Laboratory at the Institute of Infectious Diseases and Molecular Medicine (Cape Town) and has 3 years research experience as a lead investigator for a study entitled ‘Clinical deterioration during TB treatment in HIV-infected South Africans’.

Understanding how complex systems interact is why this 28-year-old with first-class honours from the University of Cape Town chose a career in infectious diseases research. His preliminary work, conducted in 2007 at a district hospital in Cape Town, found that clinical deterioration during TB treatment is an important clinical entity. In this study, 352 patients were assessed with clinical deterioration over a 3-month period, accounting for 17% of total medical admissions. More than 70% of patients had an additional illness to tuberculosis. Rifampin-resistant tuberculosis, tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) and drug-resistant bacterial infections (other than tuberculosis) were found in 12%, 14% and 4% of cases, respectively.

In light of this overwhelming burden of disease and the need to mitigate the associated co-morbidity and mortality, Dr Pepper investigated the incidence, causes and risk factors for clinical deterioration. A 9-month prospective cohort study was conducted at Site B Khayelitsha tuberculosis clinic. This clinic is an exceptionally busy, integrated TB-HIV service in Cape Town, South Africa.

After 24 weeks of follow-up, the findings were compelling: 40% (117/292) of patients experienced clinical deterioration, 26% of whom (30/117) required hospital admission for new AIDS-defining illnesses and TB-IRIS. Significant risk factors for deterioration and death were HIV infection and a low CD4 count at tuberculosis diagnosis. Surprisingly, multi-drug resistant tuberculosis, which is frequently encountered in Cape Town, was not a common reason for clinical deterioration or hospital admission. While MDR-TB is an important health care problem in South Africa, it is a facet of the much larger problem of clinical deterioration during TB treatment.

These findings have broader public health implications. This study highlights the need for more progressive strategies in ART and tuberculosis programs. Currently, HIV-infected patients present to health care services when they are already profoundly immune-suppressed. This results in a high burden of tuberculosis, which is accompanied by multiple complications during TB treatment. Dr Pepper’s work suggests that initiation of antiretroviral treatment at higher CD4 counts could alleviate the burden on overwhelmed health care services.

Further laboratory work is underway. This includes determining: 1) the unique metabolomic signatures for frequent causes of clinical deterioration, and 2) the frequency of sub-therapeutic TB drug levels in patients presenting with TB-IRIS.

Dr Pepper is passionate about scientific research which influences global practice. He intends to successfully address the health care challenges facing South Africa by combining first world technologies with novel research projects.

In addition to this prestigious EDCTP award, Dr Pepper was recently acknowledged as one of the Top 300 Young South Africans (Mail and Guardian, June issue 2009). He is also the recipient of a number of research awards, including a Fogarty International Clinical Operational Health Services Research Training Award at Johns Hopkins University, as well as a South African Tuberculosis AIDS Training grant and research training scholarship (NIH/FIC 1U2RTW007373-01A1, 1U2RTW007370).